SK Biopharmaceuticals’ shares successfully debut on the Kospi stock market
21415
post-template-default,single,single-post,postid-21415,single-format-standard,bridge-core-1.0.6,ajax_fade,page_not_loaded,,qode-title-hidden,transparent_content,qode-theme-ver-18.2,qode-theme-bridge,disabled_footer_bottom,qode_header_in_grid,wpb-js-composer js-comp-ver-6.0.5,vc_responsive

SK Biopharmaceuticals’ shares successfully debut on the Kospi stock market

In the midst of growing global interest in Korea’s biotechnology industry, SK Biopharmaceuticals debuted onto the Korean stock market, Kospi, at double its initial public offering price. SK Biopharmaceuticals’ shares began trading at ₩98,000 or A$118.03 on July 2 before reaching the permissible daily limit of 30% (₩127,000 or A$152.00) within a couple of hours.

SK Biopharmaceuticals’ success will support their ongoing research and development of drugs to treat epilepsy, schizophrenia, attention deficit hyperactivity disorder and rare neurological diseases.

Click here to read more.